Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propiopromazine is a phenothiazine derivative classified as a neuroleptic and tranquilizer primarily used in veterinary medicine. It acts mainly as an antagonist at dopamine D2 receptor and is considered a phenothiazine antipsychotic. Its primary use is to manage stress in pets and farm animals—especially for calming pigs during transport—and to aid in handling difficult or excited dogs by providing sedation and chemical restraint. Propiopromazine may also be used prior to minor surgery or diagnostic procedures in animals. The drug exerts its effects through central nervous system depression by blocking dopaminergic transmission[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propiopromazine.